1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Lipid Disorder Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Lipid Disorder Treatment Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Lipid Disorder Treatment Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Type, 2017–2031
6.3.1. Atorvastatin
6.3.2. Fluvastatin
6.3.3. Rosuvastatin
6.3.4. Simvastatin
6.3.5. Pravastatin
6.3.6. Other Drugs
6.4. Market Attractiveness Analysis, by Drug Type
7. Global Lipid Disorder Treatment Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2017–2031
7.3.1. Retail Pharmacies
7.3.2. Hospital Pharmacies
7.3.3. Online Pharmacies
7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global Lipid Disorder Treatment Market Analysis and Forecast, by Indication
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Indication, 2017–2031
8.3.1. Familial Combined Hyperlipidemia
8.3.2. Familial Defective Apolipoprotein B-100
8.3.3. Familial Dysbetalipoproteinemia
8.3.4. Familial Hypertriglyceridemia
8.3.5. Heterozygous Familial Hypercholesterolemia
8.3.6. Other Indications
8.4. Market Attractiveness Analysis, by Indication
9. Global Lipid Disorder Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Lipid Disorder Treatment Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Type, 2017–2031
10.3.1. Atorvastatin
10.3.2. Fluvastatin
10.3.3. Rosuvastatin
10.3.4. Simvastatin
10.3.5. Pravastatin
10.3.6. Other Drugs
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Retail Pharmacies
10.4.2. Hospital Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Indication, 2017–2031
10.5.1. Familial Combined Hyperlipidemia
10.5.2. Familial Defective Apolipoprotein B-100
10.5.3. Familial Dysbetalipoproteinemia
10.5.4. Familial Hypertriglyceridemia
10.5.5. Heterozygous Familial Hypercholesterolemia
10.5.6. Other Indications
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Type
10.7.2. By Distribution Channel
10.7.3. By Indication
10.7.4. By Country
11. Europe Lipid Disorder Treatment Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Type, 2017–2031
11.3.1. Atorvastatin
11.3.2. Fluvastatin
11.3.3. Rosuvastatin
11.3.4. Simvastatin
11.3.5. Pravastatin
11.3.6. Other Drugs
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Retail Pharmacies
11.4.2. Hospital Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Indication, 2017–2031
11.5.1. Familial Combined Hyperlipidemia
11.5.2. Familial Defective Apolipoprotein B-100
11.5.3. Familial Dysbetalipoproteinemia
11.5.4. Familial Hypertriglyceridemia
11.5.5. Heterozygous Familial Hypercholesterolemia
11.5.6. Other Indications
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Drug Type
11.7.2. By Distribution Channel
11.7.3. By Indication
11.7.4. By Country/Sub-region
12. Asia Pacific Lipid Disorder Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Type, 2017–2031
12.3.1. Atorvastatin
12.3.2. Fluvastatin
12.3.3. Rosuvastatin
12.3.4. Simvastatin
12.3.5. Pravastatin
12.3.6. Other Drugs
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Retail Pharmacies
12.4.2. Hospital Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Indication, 2017–2031
12.5.1. Familial Combined Hyperlipidemia
12.5.2. Familial Defective Apolipoprotein B-100
12.5.3. Familial Dysbetalipoproteinemia
12.5.4. Familial Hypertriglyceridemia
12.5.5. Heterozygous Familial Hypercholesterolemia
12.5.6. Other Indications
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Drug Type
12.7.2. By Distribution Channel
12.7.3. By Indication
12.7.4. By Country/Sub-region
13. Latin America Lipid Disorder Treatment Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Type, 2017–2031
13.3.1. Atorvastatin
13.3.2. Fluvastatin
13.3.3. Rosuvastatin
13.3.4. Simvastatin
13.3.5. Pravastatin
13.3.6. Other Drugs
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Retail Pharmacies
13.4.2. Hospital Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Indication, 2017–2031
13.5.1. Familial Combined Hyperlipidemia
13.5.2. Familial Defective Apolipoprotein B-100
13.5.3. Familial Dysbetalipoproteinemia
13.5.4. Familial Hypertriglyceridemia
13.5.5. Heterozygous Familial Hypercholesterolemia
13.5.6. Other Indications
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Drug Type
13.7.2. By Distribution Channel
13.7.3. By Indication
13.7.4. By Country/Sub-region
14. Middle East & Africa Lipid Disorder Treatment Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Type, 2017–2031
14.3.1. Atorvastatin
14.3.2. Fluvastatin
14.3.3. Rosuvastatin
14.3.4. Simvastatin
14.3.5. Pravastatin
14.3.6. Other Drugs
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Retail Pharmacies
14.4.2. Hospital Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Indication, 2017–2031
14.5.1. Familial Combined Hyperlipidemia
14.5.2. Familial Defective Apolipoprotein B-100
14.5.3. Familial Dysbetalipoproteinemia
14.5.4. Familial Hypertriglyceridemia
14.5.5. Heterozygous Familial Hypercholesterolemia
14.5.6. Other Indications
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Drug Type
14.7.2. By Distribution Channel
14.7.3. By Indication
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Pfizer Inc.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Novartis AG
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. AstraZeneca
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Merck & Co., Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Emcure Pharmaceuticals Ltd.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Teva Pharmaceuticals Industries Ltd.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Mylan N.V.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Kowa Pharmaceuticals America, Inc.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Glenmark Pharmaceuticals Ltd.
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Sun Pharmaceuticals Industries Ltd.
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. Wockhardt Limited
15.3.11.1. Company Overview
15.3.11.2. Product Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
